Analyzing the Metrics of Stocks Advertised on CNBC
Looking into some of the companies advertised on CNBC shows their riskiness for stock investors.
Charles Rotblut
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Looking into some of the companies advertised on CNBC shows their riskiness for stock investors.
Charles Rotblut
Jenna Brashear
| Share Statistics | LEXX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $9.0 | $421.0 | 8% |
|
| Shares Out (Mil) | 1.7 | 46.5 | 7% |
|
| Institutional Ownership | 75.5% | 82.0% | 45% |
|
| Float (Mil) | 1.9 | 48.3 | 5% |
|
| Beta | 0.49 | 0.68 | 27% |
|
| Avg Daily Volume (000s) | 21 | 348 | 22% |
|
| Price Change (52-week) |
(71.8%) | 52.0% | 12% |
|
| Growth | LEXX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 18.5% | 6.6% | 79% |
|
| Net Income (5yr) | (25.0%) | (1.6%) | 17% |
|
| EPS (5yr) | 14.2% | 15.1% | 55 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (140.5%) | (15.1%) | 0% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | LEXX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $0 | $289 | 0% |
|
| Net Income (TTM) (Mil) | ($8) | ($11) | 30% |
|
| EPS (TTM) | ($5.143) | ($0.600) | 7% |
|
| Operating Cash Flow (TTM) (Mil) | ($7) | ($7) | 22% |
|
| Net Cash Flow (TTM) (Mil) | ($1) | $1 | 42% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 10% |
|
| Enterprise Value (Q1) (Mil) | $3 | $331 | 6% |
|
| Valuation | LEXX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.49 | 2.27 | 45% |
|
| P/E | na | 24.1 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | LEXX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 100.0% | 69.4% | 96% |
|
| Net Margin | na | 3.9% | na |
|
| ROA | (134.2%) | (23.8%) | 3% |
|
| ROE | (150.3%) | (24.7%) | 6% |
|
| Liabilities to Assets | 9.1% | 32.0% | 5% |
|
| F-Score | 3 | 3 | 18% |
|
Lexaria Bioscience Corp. did not pass any screens on 11/18/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors